Bone morphogenetic protein 4 inhibitor

JP7594051B2Active Publication Date: 2024-12-03FUJIFILM CORP
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
JP2023113332
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-07-10
Publication Date
2024-12-03
Estimated Expiration
2040-04-30

AI Technical Summary

Benefits of technology

【0018】 本開示の技術によれば、メラノサイトの分化及び増殖の抑制に関与する機構を利用して、美白剤として有用である物質をスクリーニングことができる。さらに、スクリーニングにより有用性が確認された美白剤としてのBMP-4抑制剤、及びスクリーニングにより有用性が確認された美白剤を含有する化粧料及びその製造方法を提供することができる。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594051000002
    Figure 0007594051000002
  • Figure 0007594051000003
    Figure 0007594051000003
  • Figure 0007594051000004
    Figure 0007594051000004
Patent Text Reader

Abstract

To provide a method for screening a substance useful as a whitening agent by utilizing a mechanism involved in suppressing differentiation and proliferation of melanocytes, a BMP-4 inhibitor as a whitening agent whose usefulness is confirmed by the screening method, and a cosmetic comprising the whitening agent whose usefulness is confirmed by the screening method.SOLUTION: A method of screening for whitening agents uses as an index, decrease in an expression level of melanocyte differentiation-inducing factor in cells exposed to a whitening agent candidate substance relative to the expression level of melanocyte differentiation-inducing factor in a control group in which cells are not exposed to the whitening agent candidate substance. A BMP-4 inhibitor includes at least one of a group consisting of a burnet extract, an aloe vera leaf extract, soymilk fermented liquid, a moth bean seed extract, a horse chestnut extract, a glycyrrhiza extract, and an Angelica keiskei leaf / stem extract. A cosmetic comprises a whitening agent candidate substance whose expression level of melanocyte differentiation-inducing factor is confirmed to be reduced by the whitening agent screening method.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention , beauty Whitening obtained by screening method of whitening agent Agent Regarding. [Background technology]

[0002] Conventionally, in order to prevent skin pigmentation and maintain white and bright skin, whitening cosmetics containing various whitening active ingredients such as placenta, ellagic acid, kojic acid, tranexamic acid, cetyl tranexamate, linoleic acid, etc. For example, the following Patent Document 1 discloses a cosmetic containing a specific cysteine ​​derivative or a salt of a cysteine ​​derivative and a specific whitening agent, and discloses a number of plant extracts as the specific whitening agent.

[0003] Melanin, the black pigment of skin, is produced by pigment-producing cells called melanocytes. The following Patent Document 2 discloses a method for promoting induction of differentiation of melanocytes for the purpose of treating diseases such as vitiligo vulgaris, hereditary symmetrical pigmentary dyschromatosis, and albinism, which are caused by abnormal suppression of melanin production or a deficiency of melanocytes. Specifically, the method disclosed includes culturing human pluripotent stem cells in the presence of a component that induces epidermal cells and a component that induces terminal differentiation into keratinocytes.

[0004] In addition, the following Patent Document 3 discloses a screening method for differentiation inducers of pluripotent stem cells, and describes many factors belonging to the so-called TGF-β (transforming growth factor-β) superfamily as stem cell differentiation inducers, and describes BMP-4 (Bone Morphogenetic Protein-4) as one of the many factors. It has been reported that BMP-4 is involved in the differentiation of stem cells into retinal pigment epithelium (Patent Document 4 below) and in promoting hair growth (Patent Document 5 below). In addition, the following Patent Document 6 reports that BMP-4 reduces melanin production in melanocytes. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] International Publication No. 2013 / 081147 [Patent Document 2] JP 2015-146803 A [Patent Document 3] Special Publication No. 2005-500847 [Patent Document 4] JP 2009-226069 A [Patent Document 5] Special Publication No. 2008-534607 [Patent Document 6] Special Publication No. 2006-508026 Summary of the Invention [Problem to be solved by the invention]

[0006] Skin pigmentation is caused by the differentiation and proliferation of melanocytes from stem cells, which then increases the production of melanin. Therefore, substances that can inhibit the differentiation and proliferation of melanocytes are considered to be useful as skin whitening agents.

[0007] The present disclosure aims to screen for substances that are useful as whitening agents by utilizing a mechanism involved in the inhibition of melanocyte differentiation and proliferation, to provide a BMP-4 inhibitor as a whitening agent whose usefulness has been confirmed through screening, and to provide a cosmetic product containing a whitening agent whose usefulness has been confirmed through screening, and a method for producing the cosmetic product. [Means for solving the problem]

[0008] Specific means for solving the above problems include the following embodiments. [1] A method for screening skin whitening agents, which uses as an indicator a reduction in the expression level of a melanocyte differentiation-inducing factor when cells are exposed to a candidate skin whitening agent, relative to the expression level of the melanocyte differentiation-inducing factor in a control group in which the cells are not exposed to the candidate skin whitening agent.

[0009] [2] The method for screening a skin whitening agent according to [1], wherein the melanocyte differentiation promoter is bone morphogenetic protein 4.

[0010] [3] The method for screening a skin whitening agent according to [1] or [2], wherein the cells are normal human cells.

[0011] [4] The method for screening a skin whitening agent according to [4], wherein the normal human cells are epidermal keratinocytes.

[0012] [5] The method for screening a skin whitening agent according to [5], wherein the human normal cells are fibroblasts.

[0013] [6] A bone morphogenetic protein 4 inhibitor comprising at least one selected from the group consisting of Sanguinea baicalensis extract, aloe vera leaf extract, fermented soy milk liquid, moth bean seed extract, horse chestnut extract, licorice extract, and angelica tree leaf / stem extract.

[0014] [7] A bone morphogenetic protein 4 inhibitor described in [6], which contains particles containing Sanguinea baicalensis extract, the particles having a median diameter of less than 1 μm.

[0015] [8] A cosmetic preparation containing the bone morphogenetic protein 4 inhibitor of [6] or [7] as a whitening agent.

[0016] [9] A cosmetic preparation comprising, as a whitening agent, a candidate whitening agent substance that has been confirmed to have a reduced gene expression level of a melanocyte differentiation induction promoting factor by any of the screening methods for whitening agents described in [1] to [5].

[0017]

[10] A method for producing a cosmetic, comprising: a step of determining, as a whitening agent, a candidate whitening agent substance that has been confirmed to have a reduced expression level of a melanocyte differentiation induction promoting factor by any of the screening methods for whitening agents according to [1] to [5]; and a step of adding the whitening agent to cosmetic ingredients. Effect of the Invention

[0018] According to the technology disclosed herein, it is possible to screen for substances that are useful as skin whitening agents by utilizing the mechanism involved in the inhibition of melanocyte differentiation and proliferation. Furthermore, it is possible to provide a BMP-4 inhibitor as a skin whitening agent whose usefulness has been confirmed by screening, and a cosmetic product containing the skin whitening agent whose usefulness has been confirmed by screening, and a method for producing the cosmetic product. [Brief description of the drawings]

[0019] [Figure 1] Graph showing the melanin production effect of BMP-4. [Diagram 2] Graph showing the results of screening for candidate substances for skin whitening agents. [Diagram 3] Graph showing the effect of the presence or absence of Sanguisorba officinalis extract on melanin production. [Figure 4] Graph showing the effect of nano-sizing of Sanguisorba officinalis extract on melanin production. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] (1) Screening method for skin whitening agents The first embodiment of the screening method for whitening agents uses as an indicator a reduction in the expression level of a melanocyte differentiation-inducing factor when cells are exposed to a candidate whitening agent, relative to the expression level of the melanocyte differentiation-inducing factor in a control group in which the cells are not exposed to the candidate whitening agent.

[0021] In this embodiment, when a substance is a candidate for a whitening agent, the expression level of the melanocyte differentiation induction promoter is verified in an experimental group in which cells are exposed to the substance and in a control group in which cells are not exposed to the substance. Then, whether the expression level of the experimental group is lower than that of the control group is used as an index for screening as a whitening agent. Here, a "whitening agent candidate substance" is a candidate substance that can become a whitening agent, and refers to a test substance for screening. Also, a "whitening agent" refers to a substance that has been confirmed to have the function of lowering the expression level of the melanocyte differentiation induction promoter through screening among the candidate substances for whitening agents.

[0022] A melanocyte differentiation promoter is a protein that promotes the differentiation of pluripotent stem cells (e.g., induced pluripotent stem cells (iPS cells)) or melanocyte stem cells into melanocytes. Examples of proteins that function as melanocyte differentiation promoters include BMP-2, BMP-4, BMP-7, stem cell factor (SCF), endothelin 1, endothelin 3, and Wnt3a.

[0023] Here, the expression level of the melanocyte differentiation induction promoting factor may be confirmed by detecting the melanocyte differentiation induction promoting factor itself as a produced protein, or by detecting the expression of the corresponding gene when the melanocyte differentiation induction promoting factor is produced. That is, the expression level of the melanocyte differentiation induction promoting factor may be either the gene expression level or the protein expression level, or both.

[0024] Methods for confirming gene expression levels include, for example, polymerase chain reaction (PCR), reverse transcription PCR (RT-PCR), a method for detecting gene amount using an RNA probe (microarray method), a method for sequencing an RNA sequence using a next-generation sequencer and detecting the expression amount, and a method for detecting the expression amount using nucleic acid hybridization (in situ hybridization method).

[0025] Methods for confirming protein expression levels include a method for semi-quantitatively detecting proteins using Western blotting, a method for quantitatively detecting proteins using ELISA, a method for measuring the intensity of staining such as fluorescence in images of immunostained specimens, and a method for detecting proteins using proteome analysis.

[0026] A decrease in the expression level of the melanocyte differentiation induction promoting factor in the experimental group may be judged by whether the expression level in the experimental group is even slightly lower than that in the control group, and preferably whether the decrease rate of the expression level in the experimental group relative to that of the control group (i.e., the rate calculated by "(AX) / A", where A is the expression level in the control group and X is the expression level in the experimental group) is 5% or more, preferably 10% or more, more preferably 20% or more, and even more preferably 50% or more. Furthermore, regardless of the decrease rate, it is desirable that the difference between the expression level in the experimental group and the expression level in the control group is statistically significant. The risk rate for judging statistical significance may be 5% or less.

[0027] According to this embodiment, candidate whitening agents that may be useful as whitening agents can be screened using a decrease in the gene expression level of a melanocyte differentiation-inducing factor, which is a mechanism involved in the inhibition of melanocyte differentiation and proliferation, as an indicator, and the substances obtained by screening can be used as whitening agents.

[0028] In the screening method for a skin whitening agent of the second embodiment, the melanocyte differentiation promoter of the first embodiment is bone morphogenetic protein 4.

[0029] Among factors that can serve as indicators for melanocyte differentiation induction promoting factors in the screening method for whitening agents according to the first embodiment, a decrease in the gene expression level of bone morphogenetic protein 4 (BMP-4) can be used as an indicator to clearly screen for candidate whitening agents.

[0030] In the screening method for a skin whitening agent of the third embodiment, the cells are normal human cells in the first or second embodiment.

[0031] In the screening method for a skin whitening agent of the fourth embodiment, the normal human cells of the third embodiment are epidermal keratinocytes.

[0032] In the screening method for a skin whitening agent of the fifth embodiment, the normal human cells of the third embodiment are fibroblasts.

[0033] Melanocytes that produce melanin differentiate from melanocyte stem cells. It is presumed that the differentiation of melanocyte stem cells into melanocytes involves melanocyte differentiation-promoting factors secreted from cells present around melanocyte stem cells in the skin (e.g., human normal cells such as epidermal keratinocytes, fibroblasts, Langerhans cells, nerve cells, T cells, Merkel cells, and melanocytes, hereinafter referred to as "surrounding cells"). Therefore, if the secretion of melanocyte differentiation-promoting factors from surrounding cells can be suppressed, it is believed that the differentiation of melanocyte stem cells into melanocytes can also be suppressed, and as a result, melanin production by melanocytes can also be suppressed. Therefore, if a candidate whitening agent is exposed to human normal cells, particularly epidermal keratinocytes or fibroblasts, more preferably epidermal keratinocytes, and the expression level of melanocyte differentiation-promoting factors, such as BMP-4, in the exposed cells is reduced, this means that the candidate whitening agent exposed to the cells has the effect of suppressing melanocyte differentiation-promoting factors. It is considered that the whitening agent candidate substance exposed to the cells inhibits the differentiation of melanocyte stem cells into melanocytes through the effect of inhibiting the melanocyte differentiation induction promoter, and as a result, inhibits melanin production. That is, in the third to fifth embodiments, the whitening agent candidate substance is exposed to human normal cells, particularly epidermal keratinocytes or fibroblasts, more preferably epidermal keratinocytes, and the expression level of the melanocyte differentiation induction promoter is observed, which is considered as screening for whitening effect. It is presumed that the reason why epidermal keratinocytes are considered to be more preferable as human normal cells is that epidermal keratinocytes are located around melanocytes and therefore are likely to affect melanocytes.

[0034] (2) Bone morphogenetic protein 4 (BMP-4) inhibitors The BMP-4 inhibitor of the sixth embodiment includes at least one of the group consisting of Sanguisorba officinalis extract, Aloe vera leaf extract, fermented soy milk liquid, Moss bean seed extract, Horse chestnut extract, Licorice root extract, and Angelica keiskei leaf / stem extract.

[0035] When epidermal keratinocytes as normal human cells were exposed to various candidate substances for skin whitening agents, the extract of Sanguinea oleracea, the extract of Aloe vera leaves, the fermented soy milk, the extract of Moss Bean seeds, the extract of Horse Chestnut, the extract of Licorice Root and the extract of Angelica keiskei leaf / stem significantly suppressed the gene expression level of BMP-4, and therefore it was determined that each of the above substances has an effect as a BMP-4 inhibitor. In this way, it is expected that melanin production can be suppressed by reducing the gene expression level of BMP-4, and a skin whitening effect can be expected through the suppression of melanin production. It should be noted that, while the above-mentioned Patent Document 6 reports that BMP-4 reduces the production of melanin in melanocytes, the sixth embodiment suppresses melanin production by reducing the expression level of BMP-4 with the BMP-4 inhibitor. Here, the BMP-4 inhibitor may be each of the above substances themselves, or may be a composition in which each of the above substances is dissolved in an appropriate solvent. The composition may also be a composition containing particles of any size finely divided by using each of the above substances alone or in combination of two or more together with an appropriate solvent or with any additive.Furthermore, the composition may be an emulsion or dispersion containing each of the above substances.

[0036] Burnet extract is an extract extracted from the roots and rhizomes of great burnet (Sanguisorba officinalis), and is available, for example, as "Jiyu Extract Powder" (Maruzen Pharmaceutical Co., Ltd.). Aloe vera leaf extract is an extract extracted from the juice of the leaves of Aloe vera (Aloe vera), and is available, for example, as "Aloe Extract Vera Miyakojima" (Ichimaru Falcos Co., Ltd.). Fermented soy milk liquid is a liquid obtained by fermenting and filtering soy milk, and is available, for example, as a product of Technoble Co., Ltd. Moss bean seed extract is an extract extracted from the seeds of moth bean (Vigna aconitifolia), and is available, for example, as "VIT-A-LIKE PW LS 9898" (Yamakawa Trading Co., Ltd.). The horse chestnut extract is an extract extracted from the seeds of the horse chestnut tree (scientific name: Aesculus hippocastanum), and is available, for example, as a product of Sabinsa Japan Corporation. The licorice root extract is an extract extracted from the root of licorice (scientific name: Glycyrrhiza glabra), and is available, for example, as "Licorice Extract (Maruzen Pharmaceutical Co., Ltd.)". The angelica tree leaf / stem extract is an extract extracted from either or both of the leaves and stems of angelica tree (scientific name: Angelica keiskei), and is available, for example, as "Angelica tree extract B (Maruzen Pharmaceutical Co., Ltd.)". However, the above-mentioned acquisition methods are not limited.

[0037] The BMP-4 inhibitor of the seventh embodiment comprises particles containing a Sanguisorba officinalis extract in the sixth embodiment, and the particles have a median diameter of less than 1 μm.

[0038] Hereinafter, the BMP-4 inhibitor of the seventh embodiment is referred to as a nano-sized sanguisorba composition. The nano-sized sanguisorba composition is a sanguisorba composition containing a sanguisorba extract, and the median diameter of the particles containing the sanguisorba extract is less than 1 μm.

[0039] Here, the median diameter is defined as the diameter at which the larger and smaller particles are equal if the powder is divided into two by particle diameter. The median diameter can be measured by applying the principle of dynamic light scattering. For example, the median diameter (d50) of dispersed particles can be measured using a particle size analyzer (FPAR-1000, Otsuka Electronics Co., Ltd.).

[0040] The nano-sized Sanguinea Pig composition of the seventh embodiment can improve the melanin production suppression effect compared to a dispersion containing particles with a median diameter of 1 μm or more. The median diameter of the particles is preferably less than 200 nm, more preferably less than 100 nm, and even more preferably less than 80 nm. The lower limit of the median diameter of the particles may be 10 nm.

[0041] The particles contained in the nanoized Sanguisorba officinalis composition used in the seventh embodiment may be produced by any process such as an emulsification process or a dispersion process, so long as they are in the form of particles with a median diameter of less than 1 μm. The particles contained in the nanoized Sanguisorba officinalis composition may contain, in addition to the Sanguisorba officinalis extract, oily substances such as hydrogenated polyisobutene, squalane, isotridecyl isononanoate, and tri(capryl-caprylic acid)glyceryl.

[0042] The nanosized Sanguisorba officinalis composition of the seventh embodiment can be produced as oil droplets in an oil-in-water emulsion, for example, by suspending Sanguisorba officinalis extract in an oil phase and then emulsifying and dispersing it together with an aqueous phase.

[0043] The amount of oil phase in the nano-sized Sanguisorba officinalis composition is preferably 1% by mass to 20% by mass, more preferably 5% by mass to 17.5% by mass. When the amount of oil phase is 1% by mass or more, it is advantageous in terms of exerting the BMP-4 inhibitory effect. Also, when the amount of oil phase is 20% by mass or less, it is advantageous in terms of dispersing the Sanguisorba officinalis extract in the BMP-4 inhibitor.

[0044] The BMP-4 inhibitor of the present disclosure can be added to, for example, cosmetics, quasi-drugs, pharmaceuticals, and the like.

[0045] (3) Cosmetics and their manufacturing method The cosmetic material of the eighth embodiment contains the BMP-4 inhibitor of the sixth embodiment or any of the embodiments as a skin whitening agent.

[0046] When the BMP-4 inhibitor of the sixth or seventh embodiment is exposed to human normal cells, particularly epidermal keratinocytes or fibroblasts, the expression level of BMP-4 is reduced compared to a control group that is not exposed. Therefore, the BMP-4 inhibitor of the sixth or seventh embodiment is useful as a whitening agent that suppresses melanin production caused by a decrease in the expression level of BMP-4 inhibitor. Therefore, by incorporating the BMP-4 inhibitor in a cosmetic, a cosmetic having a whitening effect can be provided.

[0047] The cosmetic composition of the ninth embodiment contains, as a whitening agent, a candidate whitening agent substance that has been confirmed to reduce the gene expression level of a melanocyte differentiation induction promoting factor by any of the screening methods for whitening agents of the first to fifth embodiments.

[0048] The content of the candidate substance for whitening agents (e.g., Sanguisorba officinalis extract) in the cosmetic is preferably 0.0001% by mass to 0.05% by mass, and more preferably 0.001% by mass to 0.025% by mass. If the content of the candidate substance for whitening agents is 0.0001% by mass or more, it is advantageous in that a decrease in the gene expression level of the melanocyte differentiation induction promoter is observed. Also, if the content is 0.05% by mass or less, it is advantageous in that the candidate substance for whitening agents can be dispersed in the cosmetic.

[0049] The method for producing the cosmetic of the present disclosure is not particularly limited as long as it includes a step of adding a candidate substance for a whitening agent, which has been screened by the screening method for a whitening agent of the present disclosure, to the cosmetic as a whitening agent. The cosmetic ingredients will be described later. The cosmetic of the present disclosure can be obtained, for example, by mixing a specific amount of a thickener, a specific amount of a moisturizing ingredient, a specific amount of a surfactant, water, and other ingredients as necessary to prepare the cosmetic ingredients, and further adding a specific amount of a BMP-4 inhibitor as a whitening agent, according to a known production method.

[0050] In particular, the cosmetic of the present disclosure is suitably produced by the cosmetic production method of the tenth embodiment. The cosmetic production method of the tenth embodiment includes a step of determining, as a whitening agent, a candidate whitening agent substance that has been confirmed to have a reduced expression level of a melanocyte differentiation induction promoter by the screening method for whitening agents of any one of the first to fifth embodiments (hereinafter, candidate substance determination step), and a step of adding the whitening agent to the cosmetic ingredients (hereinafter, addition step).

[0051] In the candidate substance determination step, a candidate substance for a skin whitening agent is determined, which has been confirmed to have a reduced expression level of a melanocyte differentiation induction promoter by the method for screening a skin whitening agent according to any one of the above-described first to fifth embodiments. Details of the first to fifth embodiments are as described above, and therefore will not be described here.

[0052] In the addition step, the candidate substance for the whitening agent is added to the cosmetic component. The addition can be carried out by mixing the candidate substance for the whitening agent with the cosmetic component. The mixing can be carried out by a known method such as an emulsion dispersion method. In the case of using the emulsion dispersion method and the candidate whitening substance is oil-soluble, for example, an oil phase containing at least the candidate whitening substance and an aqueous phase are mixed and emulsified to obtain an oil-in-water or water-in-oil emulsion.

[0053] The oil phase may contain a candidate substance for a whitening agent, and if necessary, an emulsifier, as well as other additives, an organic solvent, etc. The candidate substance for a whitening agent is as described above, and other cosmetic components will be described later. Examples of the emulsifier include lecithin, glycerin fatty acid esters (for example, higher fatty acid esters such as polyglyceryl oleate), saponin, and sucrose fatty acid esters (for example, higher fatty acid esters such as sucrose stearate).

[0054] The aqueous phase may contain water, an emulsifier, an organic solvent, and, if necessary, other cosmetic ingredients. The candidate substances for the whitening agent are as described above, and the other cosmetic ingredients will be described later. Examples of the emulsifier include lecithin, glycerin fatty acid ester, saponin, and sucrose fatty acid ester. The organic solvent is preferably a water-soluble solvent, such as ethanol, polyhydric alcohols (butylene glycol, dipropylene glycol, glycerin, etc.).

[0055] The emulsification can be carried out in the temperature range of 20°C to 90°C. Emulsification can be carried out using a stirring device such as an ultra-high speed homogenizer or an ultrasonic homogenizer (for example, ultrasonic homogenizer device US-600AT manufactured by Nippon Seiki Seisakusho Co., Ltd.).

[0056] The cosmetic composition of the present disclosure obtained may be in any form, such as a lotion, emulsion, cream, gel, wax, facial cleansing cream, or facial cleansing foam.

[0057] According to the method for screening whitening agents of the present disclosure, a candidate substance for a whitening agent useful as a whitening agent can be selected using as an index a phenomenon that leads to a whitening effect, namely, a decrease in the gene expression level of a melanocyte differentiation induction promoter (particularly, BMP-4). In addition, by incorporating the candidate substance for a whitening agent selected by the method for screening whitening agents of the present disclosure into a cosmetic, a cosmetic having a whitening effect can be provided.

[0058] Examples of uses of the cosmetic of the present disclosure include use as cosmetics (for example, skin care cosmetics such as lotions and serums, particularly skin care cosmetics for whitening). Examples of the cosmetic include skin care cosmetics (lotions, emulsions, serums, etc.), body cosmetics (body lotions, etc.), scalp cosmetics, etc. However, the uses of the cosmetic of the present disclosure are not limited to the above.

[0059] The cosmetic of the present disclosure may appropriately contain additives that are commonly used in cosmetics as cosmetic ingredients. Examples of additives include functional ingredients (e.g., γ-oryzanol, hydrogenated polyisobutene, etc.) that exhibit useful beauty effects (e.g., moisturizing effect, skin conditioning effect, etc.) when used in cosmetics. Examples of other additives include solubilizers such as polyoxyethylene polyoxypropylene decyl tetradecyl ether (cosmetic ingredient name: PPG-6 decyl tetradeceth-20), polyoxyethylene hydrogenated castor oil, surfactants other than the specific surfactant, astaxanthin, other carotenoids other than astaxanthin (e.g., lycopene, carotene), preservatives such as phenoxyethanol and ethylhexylglycerin, colorants, thickeners, pH adjusters such as sodium hydroxide and hydrochloric acid, buffers, fragrances, antibacterial agents, ultraviolet absorbers, active oxygen removers, antimicrobial agents, anti-inflammatory agents, minerals, etc. EXAMPLES

[0060] In the following examples, the melanin production effect of BMP-4 was evaluated, and candidate substances for skin whitening agents were screened based on the evaluation results. The melanin production inhibitory effect of the Sanguisorba officinalis extract, which exhibited the most excellent effect as a BMP-4 inhibitor among the candidate substances, was examined, and the melanin production inhibitory effect of nano-sizing the Sanguisorba officinalis extract was also examined. Note that the following examples show one example of an embodiment, and the present disclosure is not limited to the examples in any way.

[0061] (1) Evaluation of the melanin production effect of BMP-4 Proteins that function as melanocyte differentiation-inducing factors include, for example, BMP-2, BMP-4, BMP-7, SCF, endothelin 1, endothelin 3, Wnt3a, etc. Of these proteins, we examined the melanin production effect of BMP-4 in inducing differentiation of iPS cells into melanocytes.

[0062] Specifically, a system for inducing melanocyte differentiation from iPS cells was created, and the effect of BMP-4 on the process of inducing differentiation into melanocytes was examined.

[0063] iPS cells (Cellular Dynamics International) were seeded on a 6-well plate, and when they reached confluence, they were switched to neural crest cell induction medium prepared according to the method described in a published literature (Cell Reports 3, 1140-1152, April 25, 2013) to obtain melanocyte stem cells (SOX10 and c-kit positive cells). The iPS cells were maintained in mTeSR1 medium (STEMCELL Technology) and cultured at 37℃ in a 5% CO2 incubator. The melanocyte stem cells obtained by the above method were further cultured in a confluent state, and the cultured melanocyte stem cells were cultured in a differentiation induction medium containing Neurobasal Medium (Gibco) supplemented with N2 and B27 supplement factors (Gibco) at the recommended concentrations, and then 1% by mass GlutaMax (Gibco) medium supplemented with 100 ng / mL SCF, 100 ng / mL Wnt3a, 250 ng / mL EDN3 (Endothelin-3), 25 ng / mL BMP-4, 3 μM CHIR99021, and 500 μM dbcAMP (dibutylyl circlic adenocine monophosphate), to induce differentiation of the stem cells into melanocytes.

[0064] Microscopic observation confirmed the appearance of melanocytes around the colonies around the 12th day. By the 21st day after induction, the emerged melanocytes were observed to further synthesize melanin. From the above, it was confirmed that this induction system can be used to reproduce the differentiation of melanocytes from stem cells and melanin synthesis. Based on these results, the effect of the presence or absence of BMP-4 on the final melanin production in this induction system was examined. As a control group, a differentiation induction medium of the same composition except that BMP-4 was not added was used and cultured under the same conditions.

[0065] Using the above differentiation induction system, the number of viable cells was measured on the 21st day after induction using MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide) reagent (MTT-100JP, Kurabo). After measuring the number of viable cells, a melanin dissolving solution (aqueous solution containing 1 mol / L NaOH and 10% by mass DMSO (dimethyl sulfoxide)) was added to each well, and the melanin was completely dissolved by heating and ultrasonicating at 50°C for 20 minutes.

[0066] After the above dissolution, 200 μL of the melanin solution after dissolving the melanin in each well was transferred to a 96-well plate, and the absorbance at 400 nm was measured at room temperature. The absorbance obtained from the measurement was corrected by the number of live cells to determine the final amount of melanin. The results of the measurement are shown in Figure 1. The vertical axis of Figure 1 shows the relative amount of melanin production when the amount of melanin production in the control group is set to 1. The bar graph with "(-)" shows the control group in which a differentiation induction medium without BMP-4 was used, and the bar graph with "(+)" shows the experimental group in which a differentiation induction medium with a BMP-4 concentration of 10 ng / mL was used. The bar graph in each group shows the average value of three samples, and the error bars show the standard deviation.

[0067] As a result of the measurement, as shown in Figure 1, the experimental group showed more than twice the amount of melanin produced as the control group. Next, a homogeneity of variance test was performed between the control group and the experimental group using an F test, and after confirming that the variances were homogeneous, a Student's t-test was performed. In Figure 1, "**" indicates that the risk rate in the Student's t-test was 1% or less. In other words, from the results in Figure 1, it can be concluded that the presence of BMP-4 significantly increased the amount of melanin produced by melanocytes.

[0068] The results of the measurements showed that BMP-4 promotes increased melanin production during differentiation. Therefore, by suppressing the gene expression level of BMP-4 in the system where melanocytes produce melanin, the amount of BMP-4 in the system is reduced, suggesting that melanin production can be suppressed, as shown in the results of the control group versus the experimental group in Figure 1.

[0069] (2) Screening of candidate substances for skin whitening agents Next, we screened for candidate substances for skin whitening agents using the decrease in the gene expression level of BMP-4 as an index. Specifically, we screened the following candidate substances 1 to 11, which are commonly believed to have skin whitening effects. Candidate substance 1: Loquat leaf extract (product name: Loquat Leaf Extract CA, Maruzen Pharmaceutical Co., Ltd.) Candidate substance 2: Clove extract (product name: Clove Extract-J, Maruzen Pharmaceutical Co., Ltd.) Candidate substance 3: Acacia extract (product name: Acacia extract, Maruzen Pharmaceutical Co., Ltd.) Candidate substance 4: Arnica flower extract (product name: Arnica extract BG, Maruzen Pharmaceutical Co., Ltd.) Candidate substance 5: Aloe vera leaf extract (product name: Aloe Ex Vera Miyakojima, Ichimaru Pharcos Co., Ltd.) Candidate substance 6: Fermented soy milk liquid (Technoble Co., Ltd.) Candidate substance 7: Moss bean seed extract (product name: VIT-A-LIKE PW LS 9898, Yamakawa Trading Co., Ltd.) Candidate substance 8: Horse chestnut extract (Sabinsa Japan Corporation) Candidate substance 9: Licorice root extract (product name: Licorice extract, Maruzen Pharmaceutical Co., Ltd.) Candidate substance 10: Angelica keiskei leaf / stem extract (product name: Angelica keiskei extract BG, Maruzen Pharmaceutical Co., Ltd.) Candidate substance 11: Sanguinea oleracea extract (product name: Jiu Extract Powder, Maruzen Pharmaceutical Co., Ltd.)

[0070] Candidate substance 1 is an extract extracted from the leaves of the loquat (scientific name: Eriobotrya japonica), candidate substance 2 is an extract extracted from the flower buds of the clove (scientific name: Syzygium aromaticum), candidate substance 3 is an extract extracted from the leaves and young branches of the gambir tree (scientific name: Uncaria gambir), and candidate substance 4 is an extract extracted from the flowers of the arnica (scientific name: Arnica montana).

[0071] Each of the above candidate substances was dissolved or suspended in a solution of DMSO and ultrapure water obtained from Milli-Q (Merck Millipore) mixed at a volume ratio of 1:1 to give a candidate substance solution with a solid content of 1 mg / mL.

[0072] Human fetal keratinocytes (nHEK, Thermo Fisher Scientific) were harvested by trypsinization and suspended in 1% PSN (penicillin-streptomycin-neomycin)-containing medium (EpiLife, Gibco). After centrifugation (300 g, 3 min, room temperature), the supernatant was removed and the cells were resuspended in the above medium. Then, 1.5 × 10 cells were placed in each well of a 12-well plate. 5 cells / cm 2 The amount of medium in each well was 1.0 mL. The day after seeding, 10 μL of each of the candidate substance solutions was added and mixed well, and the cells were allowed to stand in a CO2 incubator (37°C). The final concentration of each candidate substance was 10 ppm.

[0073] In addition, control groups were also prepared in which nHEK cells were cultured under the same conditions except that none of the candidate substances were added. Three samples were prepared for each candidate substance group and the control group, and the following measurements were performed.

[0074] One day after adding the candidate substance, the supernatant was removed from each well, washed twice with phosphate-buffered saline (PBS), and total RNA was extracted using an RNA extraction reagent (RNeasy mini Kit, QIAGEN) according to the protocol. After measuring the RNA concentration using an absorbance meter, 30 μg / μL was used as the RNA template to measure the Ct value of BMP-4 using an RT-PCR system (Mx3000P, Agilent Technologies), and the amount of BMP-4 mRNA was measured using the relative quantification method (ΔΔCt method) using RT-PCR (PrimeScript One Step RT-PCR Kit, Takara Bio) based on the measured Ct value.

[0075] The nucleotide sequence of the forward primer for the BMP-4 gene, which was the target substance of this RT-PCR, was the following nucleotide sequence 1, and the nucleotide sequence of the reverse primer was the following nucleotide sequence 2. Base sequence 1: 5'-GTCCTGCTAGGAGGCGCGAG-3' Base sequence 2: 5'-GTTCTCCAGATGTTCTTTCG-3'

[0076] In addition, as a housekeeping gene for relative quantification by RT-PCR, the nucleotide sequence of the forward primer for the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was the following nucleotide sequence 3, and the nucleotide sequence of the reverse primer was the following nucleotide sequence 4. Base sequence 3: 5'-GCACCGTCAAGGCTGAGAAC-3' Base sequence 4: 5'-TGGTGAAGACGCCAGTGGA-3'

[0077] The expression level of the BMP-4 gene quantified for each candidate substance (three samples were measured for each candidate substance, and the average value and standard deviation of the three samples are shown) is shown in the graph in Figure 2 as a relative value, with the expression level of the BMP-4 gene in the control group not exposed to the candidate substance taken as 1. The vertical axis of the graph represents the relative expression level of the BMP-4 gene, and the numbers on the horizontal axis represent the numbers of each candidate substance. Each bar graph represents the average value of three samples for each candidate substance, and the standard deviation is also shown in the error bar. However, the bar graph with "none" on the left side represents the average value of the control group, and the standard deviation is also shown in the error bar. In addition, a homogeneity of variance test was performed for each of the control group and the group exposed to each candidate substance by F-test, and after verifying that the variances of the two groups could not be said to be unequal, a Student's t-test was performed. In Figure 2, "*" indicates that the risk rate in the above t-test is greater than 1% and less than 5%, "**" indicates that the risk rate is greater than 0.5% and less than 1%, and "***" indicates that the risk rate is less than 0.1%.

[0078] From the results of FIG. 2, the substances that significantly reduced the BMP-4 gene expression level compared to the control group were the aloe vera leaf extract (candidate 5), the soy milk fermented liquid (candidate 6), the moss bean seed extract (candidate 7), the horse chestnut extract (candidate 8), the licorice extract (candidate 9), the angelica tree leaf / stem extract (candidate 10), and the Sanguisorba officinalis extract (candidate 11). Therefore, the candidates 5 to 11 are useful as BMP-4 inhibitors that reduce the BMP-4 gene expression level in epidermal keratinocytes as normal cells. The reduction rates of the BMP-4 gene expression level compared to the control group for the candidates 5 to 11 were 38.7%, 46.0%, 48.5%, 48.8%, 51.3%, 53.0%, and 84.7%, respectively. In particular, candidate substance 11, a Sanguinea pig extract, suppressed BMP-4 gene expression levels by more than 80% compared to the control group, suggesting that it has the strongest BMP-4 inhibitory effect among candidate substances 5 to 11 and is the most useful BMP-4 inhibitor.

[0079] (3) Inhibitory effect of Sanguisorba officinalis extract on melanin production Next, we examined whether the Sanguisorba officinalis extract, which had the most effective BMP-4 inhibitory effect in (2) above, exhibits an inhibitory effect on melanin production in actual cells.

[0080] Mouse melanoma cells (B-16, DS Pharma) were harvested by trypsinization and then suspended in a medium containing 1% PSN. The cells were centrifuged (300 × g, 3 min, room temperature) to remove the supernatant, and resuspended in the above medium. Then, 5 × 10 cells were placed in each well of a 12-well plate. 4 cells / cm 2 The amount of medium in each well was 1 mL. The next day, the medium was completely removed, and 1.0 mL of medium containing the desired concentration of Sanguisorba officinalis extract was added, followed by standing in a CO2 incubator (37°C).

[0081] The target concentrations were 1 ppm and 5 ppm, and stock solutions of 100 times the target concentrations of the Sanguisorba officinalis extract dissolved in DMSO were added at a ratio of 10 μL per 1 mL of medium. The final concentration of 1% DMSO was 1%. As a control group, a medium containing 1% DMSO without Sanguisorba officinalis extract was used. The test was performed using a total of three groups (n=4 each), including groups with Sanguisorba officinalis extract concentrations of 1 ppm and 5 ppm, and a control group with a concentration of 0.

[0082] Three days after seeding, the supernatant was removed from each well, washed twice with PBS, and the number of viable cells was detected using a WST reagent (Cell Counting Kit, Dojindo Laboratories). After measuring the number of viable cells, each well was washed twice with PBS, and melanin dissolving solution (1 mol / L NaOH, 10% DMSO, aqueous solution) was added and completely dissolved by ultrasonication at 50°C for 20 minutes.

[0083] After the above dissolution, 200 μL of the melanin solution after dissolving the melanin in each well was transferred to a 96-well plate, and the absorbance at 400 nm was measured at room temperature. The absorbance obtained from the measurement was corrected by the number of live cells to determine the final amount of melanin. The results of the measurement are shown in FIG. 3. The vertical axis of the figure shows the relative amount of melanin production when the amount of melanin production in the control group is set to 100%. The leftmost bar graph shows the amount of melanin production in the control group (concentration 0), the center bar graph shows the group with a 1 ppm concentration of Sanguisorba officinalis extract, and the rightmost bar graph shows the group with a 5 ppm concentration. The bar graphs in each group are the average values ​​of four samples, and the error bars show the standard deviation.

[0084] As a result of the measurement, as shown in Figure 3, it was found that the melanin production amount of the 5 ppm and 1 ppm groups was approximately 76% and 82%, respectively, compared to the control group. Next, a homogeneity test was performed between the control group and the experimental group using F-test, and after confirming homogeneity of variance, a Student's t-test was performed. In Figure 3, "*" indicates that the risk rate in the Student's t-test was greater than 1% and less than 5%. In other words, it can be concluded from the results in Figure 3 that exposure to 5 ppm and 1 ppm of Sanguisorba officinalis extract significantly reduced the amount of melanin production by melanocytes.

[0085] (4) Inhibitory effect of nano-sized Sanguinea oleifera composition on melanin production (4-1) Preparation of nano-sized Sanguinea gracilis composition Hereinafter, an example of a cosmetic composition containing a nano-sized dispersion of a Sanguisorba officinalis extract as a BMP-4 inhibitor as a skin whitening agent will be described. In this disclosure, "nanonized" is defined as a particle having a median diameter of less than 1 μm.

[0086] (4-1-1) Preparation of nano-sized and non-nanofiberized compositions [Nano-composition 1] (Oil Phase Adjustment) The following ingredients were heated to 80°C and stirred for 1 hour while maintaining the temperature at 80°C to obtain an oil phase. γ-Oryzanol: 0.5% by mass Sanguisorba officinalis extract: 1.0% by mass Hydrogenated polyisobutene: 12.5% ​​by mass Lecithin (emulsifier): 1.0% by mass

[0087] (Preparation of aqueous phase) The following ingredients were heated to 80°C and stirred for 1 hour while maintaining the temperature at 80°C to obtain an aqueous phase. Polyglyceryl-10 oleate (emulsifier): 6.7% by mass Sucrose stearate (emulsifier): 3.3% by weight Glycerin (polyhydric alcohol) 40.0% by mass Water 35.0% by mass

[0088] While maintaining the obtained 15% by mass of oil phase at 80°C, 85% by mass of water phase was added, and ultrasonic dispersion was performed for 1 minute using an ultrasonic homogenizer (US-600AT, Nippon Seiki Seisakusho). The obtained dispersion was subjected to high-pressure emulsification dispersion at a pressure of 245 MPa using a Starburst Mini (Sugino Machine) three times in total. After high-pressure emulsification dispersion, the mixture was filtered using a microfilter with an average pore size of 1 μm to prepare nano-sized composition 1 as an emulsion composition cosmetic. The content of Sanguinea gracilis extract in nano-sized composition 1 was 1.0% by mass.

[0089] [Nano-composition 2] Nanoized composition 2 as an emulsion composition cosmetic was prepared in the same manner as nanoized composition 1, except that the hydrogenated polyisobutene of nanoized composition 1 was replaced with the same amount of squalane.

[0090] [Nanocomposition 3] Nanoized composition 3 as an emulsion composition cosmetic was prepared in the same manner as nanoized composition 1, except that the hydrogenated polyisobutene of nanoized composition 1 was replaced with the same amount of isotridecyl isononanoate.

[0091] [Nanized composition 4] Nanosized composition 4, an emulsion composition cosmetic, was prepared using the same process as nanosized composition 1, except that the hydrogenated polyisobutene in nanosized composition 1 was replaced with the same amount of tri(capryl-caprylic acid)glyceryl.

[0092] [Non-nanofiber composition] The oil phase composition was added to the aqueous phase composition prepared in the same manner as for nanoized composition 1, and then the mixture was stirred for 1 minute using a propeller-type stirrer (As One) to prepare a non-nanized composition as a cosmetic.

[0093] (4-1-2) Evaluation of nanoparticles The nanosized compositions 1 to 4 and the non-nanofibrated composition were evaluated by the following methods.

[0094] [Evaluation of particle size] The obtained cosmetic preparation was diluted with Milli-Q water to a concentration of 1% by mass, and the average particle size (median size (d50)) of the dispersed particles was measured using a particle size analyzer (FPAR-1000, Otsuka Electronics Co., Ltd.).

[0095] [Evaluation of stability over time] Immediately after preparation of the obtained cosmetics, and immediately after preparation and after 3 days in a 50°C environment, each cosmetic was diluted 100 times with water and the turbidity was measured using a spectrophotometer (V-630, JASCO Corporation). The turbidity 3 days after preparation was evaluated on a 4-level scale of A, B, C, and D, from best to worst, according to the following evaluation criteria. A: The turbidity was 0.025 or less. B: The turbidity was greater than 0.025 and less than 0.2. C: The turbidity was greater than 0.2 and less than 0.5. D: Turbidity exceeds 0.5.

[0096] The evaluation results of the median size and temporal stability of the nanoized compositions 1 to 4 and the non-nanonized composition are shown in Table 1 below.

[0097] [Table 1]

[0098] From Table 1 above, it was found that the median diameter of the non-nanonized composition was 5.6 μm, whereas the median diameter of the cosmetics of nanoized compositions 1 to 4 was 51 nm for the smallest nanoized composition 1, and 115 nm for the largest nanoized composition 4, and all were nanoized. The stability over time of the cosmetics was evaluated as good, A, for nanoized composition 1 and nanoized composition 2. However, as the average particle size increased, the evaluation of stability over time worsened, B for nanoized composition 3 and C for nanoized composition 4. The non-nanonized composition with an average particle size of 5.6 μm was evaluated as the worst, D. It is believed that the particles having each median diameter in nanoized compositions 1 to 4 function as BMP-4 inhibitors as oil droplets containing the Sanguinea oleifera extract.

[0099] (4-2) Evaluation of the effect of nano-sized Sanguisorba officinalis extract on melanin production Using a skin model containing melanocytes, we investigated the whitening effect of nano-sized Sanguinea oleifera extract, which was found to have an inhibitory effect on the expression level of the BMP-4 gene. Sanguinea oleifera extract contains a lot of tannins and saponins and is a hydrophobic material that is difficult to dissolve in water, so nano-sizing it improves its penetration into the skin and is expected to have a higher whitening effect than a non-nanoized formulation. In this study, nano-sized composition 1, which had the smallest average particle size and the highest stability over time evaluation in (4-1) above, was used as the experimental group, and the whitening effect was evaluated in comparison with the control group using a non-nanoized composition.

[0100] Immediately after the melanocyte-containing skin model (MEL-300B, Kurabo) arrived at the laboratory, the culture cup was transferred to a netwell and pre-incubated for one day using maintenance medium. After pre-incubation, the cosmetics of nano-sized example 1 and non-nano-sized example were applied, and the maintenance medium was changed once every three days, and the cosmetics were applied and cultured for one week.

[0101] After one week of culture, the skin model culture cup was removed and washed with PBS, and the number of viable cells was detected using the MTT reagent mentioned in (1). After measuring the number of viable cells, the products reacted with the MTT reagent were completely removed from each skin model using isopropanol, and the melanin dissolving solution mentioned in (1) was added and completely dissolved by heating at 80°C for 1 hour.

[0102] After the dissolution, 200 μL of the melanin solution in each well was transferred to a 96-well plate, and the absorbance at 400 nm was measured at room temperature, and the amount of melanin was calculated from the absorbance obtained by the measurement. The final amount of melanin was calculated by correcting the value based on the number of viable cells.

[0103] The results are shown in Figure 4. The vertical axis of Figure 4 shows the amount of melanin produced when the amount of melanin produced in the non-nanoized composition is taken as 100%. The bar graph for "Non-nano-sized component" shows the control group, and the bar graph for "Nano-sized component" shows the experimental group. The bar graph for each group shows the average value of three samples, and the error bars show the standard deviation. In addition, a homogeneity test was performed by F-test for each of the non-nanoized composition and nanoized composition 1, and after confirming homogeneity of variance, a Student's t-test was performed. In Figure 4, "*" indicates that the risk rate in the above t-test is greater than 1% and less than 5%.

[0104] The results in Figure 4 show that application of a cosmetic containing nanoized Sanguinea officinalis extract as a BMP-4 inhibitor as a skin whitening agent reduced melanin production by 28% compared to non-nanoized cases. This shows that nanoizing Sanguinea officinalis extract improves skin permeability, thereby enhancing the melanin production inhibitory effect.

[0105] (5) Manufacturing method of cosmetics A specific example of a method for producing a cosmetic product will be described below.

[0106] (5-1) Skin whitening agents Candidate substances 1 to 11, which are candidate substances for skin whitening agents described in (2), were subjected to the screening method described in (2). Among candidate substances 5 to 11, which were confirmed to have a decreased expression level of BMP-4 as a melanocyte differentiation induction promoter, candidate substance 11, which had the most excellent BMP-4 inhibitory activity, was selected as a skin whitening agent. This Sanguisorba officinalis extract was nanoized by the method described in (4-1-1) to prepare a nanoized composition. Among the nanoized compositions listed in (4-1-1), nanoized composition 1 was used as a skin whitening agent.

[0107] (5-2) Astaxanthin-containing emulsion composition The astaxanthin-containing emulsion compositions, which are components of Cosmetics 1 to 6 and 9 below, were prepared as follows.

[0108] [Aqueous phase composition A] The following components were dissolved for 1 hour while heating at 70° C. to obtain an aqueous phase composition A. Sucrose stearate (HLB=16): 33.0g Decaglyceryl monooleate (HLB=12): 67.0g Glycerin: 450.0g Pure water: 300.0g

[0109] [Oil Phase Composition A] The following components were dissolved for 1 hour while heating at 70° C. to obtain an oil phase composition A. Krill extract: 15.0g Mixed tocopherol (Riken Vitamin, Riken E Oil 800): 32.0g Medium chain fatty acid glyceride (Kao, Coconard MT): 93.0g Lecithin (Riken Vitamin, Resion P, soybean derived): 10.0g

[0110] The aqueous phase composition A obtained above was stirred (10,000 rpm) with a homogenizer (model name: HP93, manufactured by SMT Co., Ltd.) while being kept at 70°C, and the oil phase composition A was added to the aqueous phase composition A to obtain a preliminary emulsion.

[0111] The resulting preliminary emulsion was then cooled to about 40°C and subjected to high-pressure emulsification at a pressure of 200 MPa using an Ultimizer HJP-25005 (manufactured by Sugino Machine Co., Ltd.). The resulting emulsion was then filtered through a microfilter with an average pore size of 1 μm to prepare an astaxanthin-containing emulsion composition (astaxanthin content: 0.3% by mass).

[0112] The obtained astaxanthin emulsion composition was diluted to 1% by mass with Milli-Q water, and the particle size of the dispersed particles was measured using a particle size analyzer FPAR-1000 (Otsuka Electronics Co., Ltd.), which was found to be 58 nm.

[0113] Furthermore, an equivalent emulsion composition can be obtained by replacing the krill extract with product name: Astax-ST (manufactured by Marine Daio Co., Ltd.) or product name: ASTOTS-S (Haematococcus algae extract, manufactured by Fujifilm Corporation).

[0114] (5-3) Preparation of lycopene-containing emulsion composition The lycopene-containing emulsion compositions, which are components of Cosmetics 1, 2 and 9 below, were prepared as follows.

[0115] [Aqueous phase composition B] The following components were weighed into a container and heated and mixed with stirring in a thermostatic bath at 70°C. After confirming that they were well mixed, the temperature was maintained at 70°C to obtain an aqueous phase composition B. Decaglyceryl-10 oleate (HLB=12.0, Nikko Chemicals, Decaglyn 1-OV): 8.0g Sucrose stearate (Ryoto Sugar Ester S-1670, manufactured by Mitsubishi Chemical Foods): 2.0 g Glycerin: 45.0g Purified water: up to 100g remaining

[0116] [Oil phase composition B] The following components were weighed into a container and heated and mixed for 5 minutes on a hot plate at 150° C. with stirring. After confirming that they were well mixed, an oil phase composition B was obtained. Tomato oleoresin (Lyc-O-Mato 15% (containing 15% lycopene by mass), manufactured by Sunbright): 1.14g Lecithin (Resion P (derived from soybeans), manufactured by Riken Vitamin): 1.0g Medium chain fatty acid glyceride (Coconard MT, Kao): 12.8g

[0117] The aqueous phase composition B obtained above was added to the oil phase composition B, and the mixture was stirred and mixed, and dispersed for a predetermined time using an ultrasonic homogenizer to obtain a crude dispersion. The crude dispersion obtained was then further emulsified at a high pressure of 200 MPa using an ultra-high pressure emulsifier (Ultimizer, manufactured by Sugino Machine Co., Ltd.) to prepare a lycopene-containing composition (lycopene content: 0.17% by mass).

[0118] The obtained lycopene-containing emulsion composition was diluted to 1% by mass with Milli-Q water, and the particle size of the dispersed particles was measured using a particle size analyzer FPAR-1000 (Otsuka Electronics Co., Ltd.), which was found to be 52 nm.

[0119] (5-4) Cosmetic Preparation The whitening agent obtained in (5-1) was added to each of the cosmetic ingredients listed below to produce the following Cosmetics 1 to 9.

[0120] (5-4-1) Cosmetics 1 (lotion) Cosmetic 1 was prepared by adding 0.1% by mass of the whitening agent obtained in (5-1) to the cosmetic ingredients having the composition shown below, to prepare a lotion in a conventional manner (total amount 100% by mass). Arbutin: 2.0% by mass Dipotassium glycyrrhetinate: 1.0% by mass Dipropylene glycol: 4.0% by mass Polyoxyethylene methyl glucoside: 1.0% by mass 1,3-butylene glycol: 4.0% by mass Polyethylene glycol: 1.0% by mass Ethanol: 2.0% by weight Polyoxyethylene hydrogenated castor oil (60E.O.): 0.2% by mass Phenoxyethanol: 0.3% by weight Glycerin mono-2-ethylhexyl ether: 0.2% by mass Oryzanol: 0.01% by mass Polyoxyethylene phytosterol (NIKKOL BPS-20, manufactured by Nikko Chemicals): 0.03% by mass N-acetyl-L-hydroxyproline: 1.0% by mass Water-soluble collagen: 1.0% by mass Hydrolyzed collagen: 1.0% by mass Seaweed extract (1): 1.0% by mass Astaxanthin-containing emulsion composition: 0.2% by mass Lycopene-containing emulsion composition: 0.1% by mass Magnesium ascorbyl phosphate: 1.0% by mass Sodium hyaluronate: 0.2% by weight Citric acid: 1.0% by mass Sodium citrate: appropriate amount Water: Remaining

[0121] (5-4-2) Cosmetics 2 (Serum) As cosmetic preparation 2, 0.1% by mass of the whitening agent obtained in (5-1) was added to the cosmetic ingredients having the composition shown below, and a beauty essence was prepared in a conventional manner (total amount 100% by mass). Magnesium ascorbyl phosphate: 2.0% by mass Dipotassium glycyrrhetinate: 1.0% by mass Dipropylene glycol: 4.0% by mass Glycerin: 5.0% by mass Diglycerin: 2.0% by mass 1,2-Pentanediol: 2.0% by mass Phenoxyethanol: 0.5% by weight Methyl paraoxybenzoate: 0.1% by mass Alkaline Negative Latus B-16 Polymer: 0.05% by mass Oryzanol: 0.01% by mass Polyoxyethylene phytosterol (NIKKOL BPS-20: manufactured by Nikko Chemicals): 0.03% by mass Polyoxyethylene hydrogenated castor oil (60E.O.): 0.2% by mass Centella asiatica extract: 0.01% by mass Lecithin: 0.05% by weight Citric acid: 0.7% by weight Sodium citrate: appropriate amount N-acetyl-L-hydroxyproline: 1.0% by mass Water-soluble collagen: 1.0% by mass Hydrolyzed collagen: 1.0% by mass Yeast extract (1): 1.0% by mass Astaxanthin-containing emulsion composition: 0.2% by mass Lycopene-containing emulsion composition: 0.2% by mass Water: Remaining

[0122] (5-4-3) Cosmetics 3 (cream) Cosmetic 3 was prepared by adding 0.1% by mass of the whitening agent obtained in (5-1) to the cosmetic ingredients having the composition shown below, and preparing a cream in a conventional manner (total amount 100% by mass). Arbutin: 2.0% by mass Dipotassium glycyrrhetinate: 1.0% by mass Magnesium ascorbyl phosphate: 0.1% by mass 1,2-Pentanediol: 3.0% by mass Dipropylene glycol: 7.0% by mass Concentrated glycerin: 5.0% by mass Polyethylene glycol 6000 (molecular weight: 6000): 1.0% by mass Sodium hyaluronate: 0.5% by weight Trimethylglycine: 0.5% by mass 1,3-butylene glycol: 3.0% by mass Xanthan gum: 0.5% by mass Acrylic acid / alkyl methacrylate copolymer: 0.7% by mass Squalane: 0.5% by mass Shea butter: 1.0% by mass White beeswax: 1.0% by mass Behenyl alcohol: 1.0% by mass Glyceryl monostearate: 2.0% by mass Polyoxyethylene glyceryl isostearate: 1.0% by mass Tocopherol: 0.5% by weight Astaxanthin: 0.2% by weight Water-soluble collagen: 1.0% by mass Hydrolyzed collagen solution (fish-derived): 1.0% by mass N-acetyl-L-hydroxyproline: 1.0% by mass Oryzanol: 0.01% by mass Polyoxyethylene phytosterol (NIKKOL BPS-20: manufactured by Nikko Chemicals): 0.03% by mass Polyoxyethylene hydrogenated castor oil (60E.O.): 0.2% by mass Centella asiatica extract: 0.01% by mass Lecithin: 0.1% by weight Sucrose fatty acid ester: 0.1% by mass Polyglyceryl monooleate: 0.1% by mass Citric acid: 0.7% by weight Sodium citrate: appropriate amount Phenoxyethanol: 0.3% by weight Purified water: remaining

[0123] (5-4-4) Cosmetics 4 (Sunscreen) Cosmetic 4 was prepared by adding 0.1% by mass of the whitening agent obtained in (5-1) to the cosmetic components having the composition shown below, to prepare a sunscreen in a conventional manner (total amount 100% by mass). Cyclopentasiloxane: 20.0% by mass Dimethicone mass%: 10.0 mass% Titanium oxide: 5.0% by mass t-Butyl methoxybenzoylmethane: 1.0% by mass HXMT-100ZA (manufactured by Teika, average primary particle size 15 nm): 6.0% by mass Aluminum hydroxide: 1.0% by mass Isostearic acid: 0.5% by mass Sorbitan sesquioleate: 1.0% by mass Dipotassium glycyrrhetinate: 0.5% by mass Magnesium ascorbyl phosphate: 0.1% by mass Krill extract: 0.5% by mass Water-soluble collagen: 1.0% by mass Citric acid: 0.7% by weight Sodium citrate: appropriate amount Tocopherol: 0.5% by weight Oryzanol: 0.01% by mass Polyoxyethylene phytosterol (NIKKOL BPS-20: manufactured by Nikko Chemicals): 0.03% by mass Polyoxyethylene hydrogenated castor oil (60E.O.): 0.2% by mass Centella asiatica extract: 0.01% by mass Lecithin: 0.1% by weight Fragrance: Trace amount Methyl paraoxybenzoate: 0.15% by mass Purified water: remaining

[0124] (5-4-5) Cosmetics 5 (lotion) [Oil phase composition C] An oil phase composition C was prepared by adding 0.1% by mass of the whitening agent obtained in (5-1) to the cosmetic components having the following composition. Haematococcus algae extract: 0.2% by mass Astaxanthin-containing emulsion composition: 0.4% by mass Squalane: 8.0% by mass Jojoba oil: 7.0% by weight Cetyl alcohol mass%: 1.5 mass%

[0125] [Aqueous phase composition C] In addition, the cosmetic ingredients having the following composition were mixed to prepare an aqueous phase composition C. Glycerin monostearate: 2.0% by mass Polyoxyethylene cetyl ether: 3.0% by mass Polyoxyethylene isorbitan monooleate: 2.0% by mass 1,3-butylene glycol: 1.0% by mass Glycerin: 2.0% by mass Sucrose stearate: 0.1% by weight Polyglyceryl-10 oleate: 0.1% by mass Polyglyceryl-2 stearate: 0.1% by mass Phenoxyethanol: 0.2% by weight Collagen: 1.0% by mass Oryzanol: 0.01% by mass Polyoxyethylene phytosterol (NIKKOL BPS-20, manufactured by Nikko Chemicals): 0.03% by mass Polyoxyethylene hydrogenated castor oil (60E.O.): 0.2% by mass Centella asiatica extract: 0.01% by mass Lecithin: 0.05% by weight Arbutin: 0.5% by mass Dipotassium glycyrrhetinate: 0.5% by mass Citric acid: 1.0% by mass Sodium citrate: appropriate amount Fragrance: Trace amount Purified water: remaining

[0126] The above oil phase composition C and aqueous phase composition C were each heated to 70° C. and stirred while emulsifying, to prepare an emulsion as cosmetic preparation 5 (total amount 100% by mass).

[0127] (5-4-6) Cosmetic 6 (jelly-like serum) Cosmetic 6 was prepared by adding 0.1% by mass of the whitening agent obtained in (5-1) to the cosmetic ingredients having the composition shown below, to prepare a jelly-like serum in a conventional manner (total amount 100% by mass). Haematococcus algae extract: 0.1% by mass Astaxanthin-containing emulsion composition: 0.2% by mass Ceramide III and VI mixture: 1.0% by mass Hydrolyzed collagen: 1.0% by mass Acetylhydroxyproline: 1.0% by mass Ethylhexylglycerin: 0.1% by mass Oleic acid: 0.5% by weight 1,3-butylene glycol: 1.0% by mass Glycerin: 2.0% by mass Sucrose: 0.1% by weight Polyglyceryl-10 oleate: 0.1% by mass Polyglyceryl-2 stearate: 0.1% by mass Phenoxyethanol 0.2% by weight Collagen: 1.0% by mass Oryzanol: 0.01% by mass Polyoxyethylene phytosterol (NIKKOL BPS-20: manufactured by Nikko Chemical Co., Ltd.): 0.03% by mass Polyoxyethylene hydrogenated castor oil (60E.O.): 0.2% by mass Centella asiatica extract: 0.01% by mass Lecithin: 0.1% by weight Citric acid: 1.0% by mass Sodium citrate: appropriate amount (PEG-240 / Decyltetradeceth-20 / HDI) copolymer: 0.3% by mass Damask rose flower oil: trace amount Fragrance: Trace amount Purified water: remaining

[0128] (5-4-7) Cosmetics 7 (Wet Foundation) 0.1% by mass of the whitening agent obtained in (5-1) was added to the cosmetic components of the composition shown below to prepare a slurry, which was then filled into a specified container and dried to produce a solid powder cosmetic (wet foundation) as cosmetic 7 (total amount 100% by mass). Talc (OTS-2 TALK JA-46R, manufactured by Daito Kasei): 18% by mass Titanium oxide (OTS-2 TiO2 CR-5, manufactured by Daito Kasei): 9.0% by mass Iron oxide yellow (OTS-2 YELLOW LLXLO, manufactured by Daito Kasei): 2.3% by mass Iron oxide red (OTS-2 RED R-516L, manufactured by Daito Kasei): 0.15% by mass Iron oxide black (OTS-2 BLACK BL-100, manufactured by Daito Kasei): 0.3% by mass Pearl pigment (gold) (Rona Flare Balance Gold, Merck): 13% by mass Pearl pigment (red) (Transprismar Red, Merck): 7.0% by mass Composite powder pigment (HNB RED7, manufactured by Daito Kasei Kogyo): 1.0% by mass Dimethicone trimethylsiloxysilicate (DC593, manufactured by Toray Dow Corning): 3.0% by mass Dimethicone (SH200C-20cs, manufactured by Toray Dow Corning): 7.0% by mass Phenoxyethanol: 0.5% by weight Sericite (OTS-2 SERICITE FSE, manufactured by Daito Kasei): remaining amount

[0129] (5-4-8) Cosmetics 8 (Liquid Foundation) Cosmetic 8 was prepared by adding 0.1% by mass of the whitening agent obtained in (5-1) to the cosmetic components having the composition shown below, to prepare a liquid foundation (W / O emulsion) in a conventional manner (total amount 100% by mass). Dipotassium glycyrrhizinate: 0.2% by mass Specific red composite pigment (HNB RED7, manufactured by Daito Kasei): 0.5% by mass Extender pigment (OTS-2 SERICITE PSE and OTS-2 TALK JA-46R (both manufactured by Daito Kasei) mixed in a ratio of 7:3): 15.0% by mass Color pigment (OTS-2 TiO2 CR-50, OTS-2 YELLOW LLXLO, OTS-2 RED R-516L, and OTS-2 BLACK BL-100 (all manufactured by Daito Kasei) mixed in a ratio of 78:19:1:2): 2.0% by mass Pearl pigment (a mixture of Nafrea Balance Gold and Lance Prisma Red (both manufactured by MERCK) in a ratio of 7:3): 3.0% by mass Cyclomethicone: 25.0% by mass Dimethicone polyol: 5.0% by mass Lauryl PEG-9 polydimethylsiloxyethyl dimethicone: 3.0% by mass PEG-9 polydimethylsiloxyethyl dimethicone: 1.2% by weight Squalane: 0.1% by mass Sorbitan sesquiisostearate: 1.0% by mass Disteardimonium hectorite: 0.8% by mass Ethylhexyl methoxycinnamate: 2.5% by mass Haematococcus pluvialis oil: 0.1% by mass Tocopherol: 0.1% by weight Damask rose flower oil: trace amount Fragrance: Appropriate amount Phenoxyethanol: 0.3% by weight Glycerin: 10.0% by mass Dipropylene glycol: 4.0% by mass 1,3-butylene glycol: 3.0% by mass Water-soluble collagen: 0.1% by mass Royal jelly extract: 0.1% by mass Oryzanol: 0.01% by mass Polyoxyethylene phytosterol (NIKKOL BPS-20: manufactured by Nikko Chemicals): 0.03% by mass Polyoxyethylene hydrogenated castor oil (60E.O.): 0.2% by mass Centella asiatica extract: 0.01% by mass Lecithin: 0.1% by weight Calcium chloride: 1.0% by mass Citric acid: 1.0% by mass Sodium citrate: appropriate amount Ion exchange water: remaining amount

[0130] (5-4-9) Cosmetics 9 (Facial cleanser) Cosmetic 9 was prepared by adding 0.1% by mass of the whitening agent obtained in (5-1) to the cosmetic components having the composition shown below, to prepare a face wash in a conventional manner (total amount 100% by mass). Potassium myristate: 2.0% by mass Potassium palmitate: 0.5% by mass Potassium stearate: 0.5% by mass (Lauramide / Miristamide) DEA: 1.0% by mass Sodium cocoyl glycine: 10.0% by mass Sodium lauroampho: 13.0% by mass PEG-32: 3.0% by mass Butylene glycol: 15.0% by mass Glycerin: 10.0% by mass Sorbitol: 5.0% by mass Potassium hydroxide: appropriate amount Glyceryl stearate: 1.5% by weight Haematococcus pluvialis oil: 0.05% by mass Astaxanthin-containing emulsion composition: 0.05% by mass Lycopene-containing emulsion composition: 0.1% by mass Water-soluble collagen: 1.0% by mass Tocopherol: 0.5% by weight Citric acid: 1.0% by mass Sodium citrate: appropriate amount Shea butter: 1.0% by mass Polyquaternium-7: 0.5% by mass Polyquaternium-39: 0.5% by mass Sodium lauroyl glutamate: 1.0% by mass Oryzanol: 0.01% by mass Polyoxyethylene phytosterol (NIKKOL BPS-20, manufactured by Nikko Chemicals): 0.03% by mass Polyoxyethylene hydrogenated castor oil (60E.O.): 0.2% by mass Centella asiatica extract: 0.01% by mass Phenoxyethanol: 0.5% by weight Damask rose flower oil: trace amount Fragrance: Trace amount

[0131] (5-4-10) Cosmetics 10 (Serum) Cosmetic 10 was prepared by adding 0.1% by mass of the whitening agent obtained in (5-1) to the cosmetic ingredients having the composition shown below, to prepare a beauty essence in a conventional manner (total amount 100% by mass). Magnesium ascorbyl phosphate: 2.0% by mass Dipotassium glycyrrhetinate: 1.0% by mass Dipropylene glycol: 4.0% by mass Sanguinea oleracea extract (product name: Jiyu Extract Powder, Maruzen Pharmaceutical Co., Ltd.): 0.001% by mass Glycerin: 5.0% by mass Diglycerin: 2.0% by mass 1,2-Pentanediol: 2.0% by mass Phenoxyethanol: 0.5% by weight Methyl paraoxybenzoate: 0.1% by mass Alkaline Negative Latus B-16 Polymer: 0.05% by mass Oryzanol: 0.01% by mass Polyoxyethylene phytosterol (NIKKOL BPS-20: manufactured by Nikko Chemicals): 0.03% by mass Polyoxyethylene hydrogenated castor oil (60E.O.): 0.2% by mass Centella asiatica extract: 0.01% by mass Lecithin: 0.05% by weight Citric acid: 0.7% by weight Sodium citrate: appropriate amount N-acetyl-L-hydroxyproline: 1.0% by mass Water-soluble collagen: 1.0% by mass Hydrolyzed collagen: 1.0% by mass Yeast extract (1): 1.0% by mass Astaxanthin-containing emulsion composition: 0.2% by mass Lycopene-containing emulsion composition: 0.2% by mass Nicotinamide: 5.0% by mass Water: Remaining

Claims

1. A bone morphogenetic protein 4 inhibitor containing a Sanguinea pig extract.

2. The bone morphogenetic protein 4 inhibitor according to claim 1 , comprising particles containing the Sanguisorba officinalis extract, the particles having a median diameter of less than 1 μm.

3. The bone morphogenetic protein 4 inhibitor according to claim 2 , wherein the particles containing the Sanguisorba officinalis extract are an oil-in-water emulsion.

4. The bone morphogenetic protein 4 inhibitor according to claim 2 or 3, wherein the median diameter of particles containing the Sanguisorba officinalis extract is 10 nm or more and less than 200 nm.

Citation Information

Patent Citations

  • Beautifying cosmetic

    JP1988303910A

  • Skin-bleaching cosmetic

    JP2000143479A

  • Cosmetic

    JP2000302661A

  • Screening assays for identification of differentiation-inducing agents and preparation of differentiated cells for cell therapy

    JP2005500847A

  • How to lighten skin and hair

    JP2006508026A